Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

New genetic testing technology for IVG embryos

Researchers at the Johns Hopkins University School of Medicine have devised a new technique, which helps couples that are affected by or are carriers of genetic diseases have in vitro fertilized babies free of both the disease in question and other chromosomal abnormalities. The results were reported in the April issue of Fertility and Sterility.

23 May 2011

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver).

23 May 2011

Researchers discover new genes that influence severity of cystic fibrosis

Johns Hopkins Institute for Genetic Medicine researchers working as part of the North American Cystic Fibrosis Consortium have discovered two regions of the genome that affect the severity of cystic fibrosis, a genetic condition that causes scarring throughout the body, affecting most notably the pancreas and lungs.

23 May 2011

Medivir reports positive results from ASPIRE TMC435 phase 2b study for genotype 1 chronic hepatitis C

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced results from the ASPIRE phase 2b study that evaluates the addition of once daily TMC435 to pegylated interferon and ribavirin in patients with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon (PegIFN) and ribavirin (RBV) was unsuccessful either because they relapsed, had a partial response or had a null response.

20 May 2011

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, will be presenting data from the NeuVax Phase II adjuvant breast cancer clinical trial at the 2011 annual meeting of The American Society of Clinical Oncology in Chicago.

19 May 2011

Stem cells from kidneys - World first from Australian scientists

According to Australian scientists, their latest stem cell research breakthrough will bring new treatments for a growing epidemic of chronic kidney disease. They are the first in the world to generate a type of stem cell from human kidney cells. The Melbourne scientists are hoping their discovery will have far-reaching effects in treating the disease.

19 May 2011

Mpex, Synteract partner for cystic fibrosis fundraising event

Synteract, Inc., a full-service, global contract research organization, and Mpex Pharmaceuticals, a biopharmaceutical company developing new therapies to combat the growing issue of antibiotic resistance, have partnered for the second annual Great Strides fundraiser to benefit cystic fibrosis.

19 May 2011

Synergy expands GC-C agonist technology to lower cholesterol

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has successfully completed preclinical in vitro research demonstrating the inhibition of bile acid uptake by GC-C agonists and that it plans to commence animal studies shortly. Synergy believes this is the first time that GC-C agonists have been shown to potentially lower cholesterol.

18 May 2011

Restrictive gadolinium-based contrast agent guidelines help prevent nephrogenic systemic fibrosis

A simple blood test may help prevent a serious complication associated with a contrast agent commonly used in MRI exams, according to a study published in the July issue of Radiology.

18 May 2011

Viewpoints: Ryan on 'shared scarcity'; Romney fallout; Baltimore's ambitious health plan

Too many in Washington remain fixated on the next election, at the expense of the next generation. But there is a hidden cost to the shared scarcity mentality — a cost measured in lost prosperity and lost freedom. We face a choice between two futures. We can continue to go down the path toward shared scarcity, or we can choose the path of renewed prosperity.

17 May 2011

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

InterMune, Inc. today announced that an oral presentation and a poster presentation related to the company's development program for pirfenidone in idiopathic pulmonary fibrosis will be presented at the 2011 International Conference of the American Thoracic Society, being held in Denver May 13-18, 2011.

16 May 2011

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

InterMune, Inc. today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF).

16 May 2011

Pro-Pharmaceuticals reports net loss of $2.7 million for first quarter 2011

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the first quarter, ended March 31, 2011.

13 May 2011

Aradigm first quarter total revenue decreases to $0.2 million

Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2011.

12 May 2011

Amira to present AM152 preclinical data in fibrotic disease at ATS Annual Meeting

Amira Pharmaceuticals, Inc. announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society in Denver, Colorado.

12 May 2011

GSK, NanoBio initiate two NB-001 Phase 3 trials in cold sores

NanoBio Corporation today announced the initiation of two Phase 3 multicenter trials evaluating NB-001 as a topical treatment for cold sores, a step forward in their OTC licensing agreement with GlaxoSmithKline Consumer Healthcare.

12 May 2011

Scleroderma is an independent determinant for coronary calcification, study suggests

A new study by researchers in Hong Kong suggests that systemic sclerosis is an independent determinant for moderate to severe coronary calcification or atherosclerosis.

11 May 2011

16-year-old uses supercomputing network to invent new drug cocktail for cystic fibrosis

While many 16-year-olds are content with PlayStation, Toronto-area student Marshall Zhang used the Canadian SCINET supercomputing network to invent a new drug cocktail which could one day help treat cystic fibrosis.

11 May 2011

Research suggests systemic sclerosis is an independent risk factor for atherosclerosis

A new study by researchers in Hong Kong suggests that systemic sclerosis is an independent determinant for moderate to severe coronary calcification or atherosclerosis. Conventional cardiovascular risk factors such as age and hypertension predispose patients with systemic sclerosis to plaque build-up in the heart arteries similar to the general population. Details of this study are now available in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR).

10 May 2011

Insmed first quarter revenues decrease to $1.6 million

Insmed Incorporated, a biopharmaceutical company, today reported results for the first quarter ended March 31, 2011.

10 May 2011

Fibrosis News and Research

Further Reading

New genetic testing technology for IVG embryos

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Researchers discover new genes that influence severity of cystic fibrosis

Medivir reports positive results from ASPIRE TMC435 phase 2b study for genotype 1 chronic hepatitis C

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

Stem cells from kidneys - World first from Australian scientists

Mpex, Synteract partner for cystic fibrosis fundraising event

Synergy expands GC-C agonist technology to lower cholesterol

Restrictive gadolinium-based contrast agent guidelines help prevent nephrogenic systemic fibrosis

Viewpoints: Ryan on 'shared scarcity'; Romney fallout; Baltimore's ambitious health plan

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

Pro-Pharmaceuticals reports net loss of $2.7 million for first quarter 2011

Aradigm first quarter total revenue decreases to $0.2 million

Amira to present AM152 preclinical data in fibrotic disease at ATS Annual Meeting

GSK, NanoBio initiate two NB-001 Phase 3 trials in cold sores

Scleroderma is an independent determinant for coronary calcification, study suggests

16-year-old uses supercomputing network to invent new drug cocktail for cystic fibrosis

Research suggests systemic sclerosis is an independent risk factor for atherosclerosis

Insmed first quarter revenues decrease to $1.6 million

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News